Document is current
Any future updates will be listed below
-
Authors
Aoyama, Daisetsu https://orcid.org/0000-0002-9175-4881
Miyazaki, Shinsuke
Tsuji, Toshihiko
Nomura, Ryohei
Kakehashi, Shota
Mukai, Moe
Ikeda, Hiroyuki
Ishida, Kentaro
Uzui, Hiroyasu
Tada, Hiroshi
-
Funding
Funding for this research was provided by:
Daiichi-Sankyo
Biotronik
Bristol-Myers Squibb
Boehringer Ingelheim
Bayer Yakuhin
ALVAUS Co
Novartis Pharma
Ono Pharmaceutical
Takeda Pharmaceutical Company
Medtronic
Boston Scientific Corporation
Johnson and Johnson
- License Information
-
More Information
Article History
Received: 9 November 2022
Accepted: 18 January 2023
First Online: 23 February 2023
Declarations
:
: Hiroshi Tada received honoraria (lecture fees) from Daiichi-Sankyo Co., Ltd., Biotronik Japan, Inc., Bristol-Myers Squibb, and Boehringer Ingelheim and grants from Bayer Yakuhin, Ltd., Japan, Boehringer Ingelheim Japan, ALVAUS Co., Ltd., Novartis Pharmaceuticals Japan, ONO PHARMACEUTICAL CO., LTD, and Takeda Pharmaceutical Company, Ltd. Shinsuke Miyazaki received honoraria (lecture fees) from Boehringer Ingelheim, Bristol-Myers Squibb, Medtronic Japan, Boston Scientific Co., and Daiichi-Sankyo Co., Ltd., and scholarship from Johnson & Johnson.
: The study was approved by the Research Ethics Committee of University of Fukui (no. 20210132) and clinical trial registration (UMIN000046170).
